IBDEI0G9 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7894,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7894,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,7894,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,7895,0)
 ;;=67028^^57^602^1^^^^1
 ;;^UTILITY(U,$J,358.3,7895,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7895,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,7895,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,7896,0)
 ;;=J9035^^57^602^3^^^^1
 ;;^UTILITY(U,$J,358.3,7896,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7896,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,7896,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,7897,0)
 ;;=J2778^^57^602^5^^^^1
 ;;^UTILITY(U,$J,358.3,7897,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7897,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,7897,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,7898,0)
 ;;=J3301^^57^602^4^^^^1
 ;;^UTILITY(U,$J,358.3,7898,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7898,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,7898,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,7899,0)
 ;;=J0178^^57^602^2^^^^1
 ;;^UTILITY(U,$J,358.3,7899,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7899,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,7899,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,7900,0)
 ;;=4450F^^57^603^2^^^^1
 ;;^UTILITY(U,$J,358.3,7900,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7900,1,2,0)
 ;;=2^Self-Care Ed Provided to Pt
 ;;^UTILITY(U,$J,358.3,7900,1,3,0)
 ;;=3^4450F
 ;;^UTILITY(U,$J,358.3,7901,0)
 ;;=4177F^^57^603^3^^^^1
 ;;^UTILITY(U,$J,358.3,7901,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7901,1,2,0)
 ;;=2^Talk Pt/Crgvr Re AREDS
 ;;^UTILITY(U,$J,358.3,7901,1,3,0)
 ;;=3^4177F
 ;;^UTILITY(U,$J,358.3,7902,0)
 ;;=4174F^^57^603^1^^^^1
 ;;^UTILITY(U,$J,358.3,7902,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7902,1,2,0)
 ;;=2^Couns Potent Glauc Impct
 ;;^UTILITY(U,$J,358.3,7902,1,3,0)
 ;;=3^4174F
 ;;^UTILITY(U,$J,358.3,7903,0)
 ;;=373.32^^58^604^48
 ;;^UTILITY(U,$J,358.3,7903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7903,1,3,0)
 ;;=3^Eyelid,Dermatitis,Allergic
 ;;^UTILITY(U,$J,358.3,7903,1,4,0)
 ;;=4^373.32
 ;;^UTILITY(U,$J,358.3,7903,2)
 ;;=^269061
 ;;^UTILITY(U,$J,358.3,7904,0)
 ;;=373.00^^58^604^4
 ;;^UTILITY(U,$J,358.3,7904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7904,1,3,0)
 ;;=3^Blepharitis
 ;;^UTILITY(U,$J,358.3,7904,1,4,0)
 ;;=4^373.00
 ;;^UTILITY(U,$J,358.3,7904,2)
 ;;=Blepharitis^15271
 ;;^UTILITY(U,$J,358.3,7905,0)
 ;;=373.2^^58^604^7
 ;;^UTILITY(U,$J,358.3,7905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7905,1,3,0)
 ;;=3^Chalazion
 ;;^UTILITY(U,$J,358.3,7905,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,7905,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,7906,0)
 ;;=374.84^^58^604^29
 ;;^UTILITY(U,$J,358.3,7906,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7906,1,3,0)
 ;;=3^Eyelid Cysts
 ;;^UTILITY(U,$J,358.3,7906,1,4,0)
 ;;=4^374.84
 ;;^UTILITY(U,$J,358.3,7906,2)
 ;;=^269119
 ;;^UTILITY(U,$J,358.3,7907,0)
 ;;=374.87^^58^604^31
 ;;^UTILITY(U,$J,358.3,7907,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7907,1,3,0)
 ;;=3^Eyelid Dermatochalasis
 ;;^UTILITY(U,$J,358.3,7907,1,4,0)
 ;;=4^374.87
 ;;^UTILITY(U,$J,358.3,7907,2)
 ;;=^269123
 ;;^UTILITY(U,$J,358.3,7908,0)
 ;;=375.15^^58^604^12
 ;;^UTILITY(U,$J,358.3,7908,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7908,1,3,0)
 ;;=3^Dry Eye Syndrome
 ;;^UTILITY(U,$J,358.3,7908,1,4,0)
 ;;=4^375.15
 ;;^UTILITY(U,$J,358.3,7908,2)
 ;;=Dry Eye Syndrome^37168
 ;;^UTILITY(U,$J,358.3,7909,0)
 ;;=374.01^^58^604^20
 ;;^UTILITY(U,$J,358.3,7909,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7909,1,3,0)
 ;;=3^Entropion, Senile
